Slide 1: Elevating the World's Wellbeing
Elevating the World’s Wellbeing
Slide 2: Forward-looking statement
Forward-looking statement This presentation contains certain forward-looking statements and opin- actual results, including the Company's cash flow, financial condition and ions. Forward-looking statements are statements that do not relate to results of operations, to differ materially from the resu
Slide 3: Agenda
Agenda Q2 in short Business updates Financial results Strategy and outlook Q&A Henrik Molin Charlotte Goodwin CEO & co-founder CFO
Slide 4: Q2 in short
B Q2 in short
Slide 5: Quarterly Progress
The Group has faced a financially challenging environment during the quarter, however the Group continues to post positive growth 5% 21% €0.8m 24% Quarterly Subscription Q2 2024 cash flow Adjusted EBITDA YTD revenue growth revenue grown negative increased to Current annualised Extended Santander fac
Slide 6: Business Updates
a SS — = a ‘ at HN \ li 'y 7 Business Updates
Slide 7: Our two business lines have us well-positioned to capitalize on digital healthcare demand
Our two business lines have us well-positioned to capitalize on increasing digital healthcare demand and corporate wellbeing challenges. Wellness One platform, all areas of employee wellbeing Technology for employers Lifecare Seamless and efficient care solutions Technology for healthcare providers
Slide 8: Lifecare quarterly developments
Lifecare quarterly developments Q2 Highlights 16% growth in license numbers within Lifecare User base and subscription revenue of the platform continue to grow quarterly (21% year on year). 66,000 Our partnership with Business Finland has been expanded during the quarter 64,000 allowing the expansio
Slide 9: Wellness quarterly developments
Wellness quarterly developments Q2 Highlights YTD revenue, Wellness segment Champion Health+ developed an AI-powered self-service MSK tool (Nexa) for 2.9 its corporate customers. 5% We launched Champion Health 3.0 and finalised the localisation of the platform and content in Swedish and German to ex
Slide 10: Innovation
Innovation During Q3 our major product developments will be through: Finalisation of the rollout of Physitrack AI Assistant (mobile app). Rollout of Nexa to Champion Health+ customers, medical device certification and continued enhancements. Rollout of the Champion Health platform and content in Swe
Slide 11: Financial Results
no 2 5 n o) ag © oO Cc oO & Le |
Slide 12: Q2 Financial Highlights
Q2 Financial Highlights 6 months revenue 6 months EBITDA €8.1m (Q2 2023: €7.5m) 8% €1.7m (Q2 2023: €1.4m) 16% 6 months subscription revenue 6 months cashflow €6.5m/81% 21% €1.5m (Q2 2023: €1.2m) 19% (Q2 2023: €5.3m/71%) 6 months adjusted EBITDA 6 months adjusted EBITDA margin -1pp €2.0m (Q2 2023: €1
Slide 13: Maintaining revenue growth
Q Q 1 2 Maintaining revenue growth Group Revenue 4.5 Li fe care revenue growth 3.0 Wellness revenue growth 2.5 5% 4.0 10% 2.5 3.5 2.0 3.0 2.0 -2% 1.5 2.5 1.5 2.0 1.0 1.5 1.0 1.0 0.5 0.5 0.5 - - - Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q1 Q2 Q3 Q4 Q1 Q2 Q3
Slide 14: Significant growth in subscription revenue
Significant growth in subscription revenue 90% 3.5 80% 82% 80% 78% 75% 3.0 72% 72% 71% 70% 68% 70% 2.5 60% 60% 54% 2.0 50% 44% 40% 1.5 30% 1.0 20% 23% 22% 21% 16% 0.5 10% 0% Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Subscription revenue Proportion of total reven
Slide 15: Adjusted EBITDA
Adjusted EBITDA EBITDA by division 4.5 4 3.5 1.0 2.5 48% 3 Q2 2024 0.1 2% 2.5 (0.6) 1.1 4% 2 1.5 0.9 2.3 48% 1.0 Q2 2023 0.1 4% 1 (0.5) 0.5 1.1 0.9 (1.0) (0.5) - 0.5 1.0 1.5 2.0 2.5 3.0 0 2023 ADJ EBITDA 2024 ADJ EBITDA Lifecare Wellness Group Q1 Q2 Q3 Q4
Slide 16: Cashflow
Cashflow €1.7m 1 Jan 2024 Opening Adjusted EBITDA Working capital Interest expense Purchase of intangibles Adjusting items Net drawdown of Fx 30 June 2024 Closing Net cash borrowings net cash
Slide 17: Cash-flow impacted by seasonal impacts of working capital
Cash-flow impacted by seasonal impacts of working capital 0.4 0.2 - Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 (0.2) (0.4) (0.6) (0.8) (1.0) (1.2) (1) Free cash flow is defined as net cash from operating activities, less purchase of intangible assets and property, plant and equipmen
Slide 18: Balance sheet
Balance sheet 30 June 2024 30 June 2023 Euros ’000 Goodwill, intangibles and PE 34,154 37,751 Cash and cash equivalents 569 673 Borrowings (4,330) (3,694) Trade and other receivables 3,758 3,334 Trade and other payables (2,320) (2,095) Deferred revenue (1,988) (1,700) Deferred tax (1,080) (1,358) De
Slide 19: Strategy and Outlook
i Strategy and Outlook
Slide 20: Our unique value proposition
Our unique value proposition Holistic offering, powered by top-of-the-line tech True product market fit Prices in relation to the market rather than growth expectations Catering to consumer trends Improved patient outcomes through more personalized, data-driven care Positioned to capitalize on growt
Slide 21: How it all comes together - investing in Physitrack
How it all comes together - investing in Physitrack Market outlook and position Focus Areas High-reaching financial goals Top-line growth Physitrack aims to achieve a doubling of revenue within the medium term. Growing market supported by 1. Market growth dynamics underlying macro trends Profit marg
Slide 22: Q&A
Q&A